Product Information
ERYTHROMYCIN 2% GEL is a generic product labeled by Padagis Israel Pharmaceuticals Ltd, priced at $0.6726 per GM under NDC 45802096694. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 29, 1993. Its Orange Book therapeutic-equivalence code is AT.
Strength
20 mg/g
Manufacturer
Padagis Israel Pharmaceuticals LtdNDC
45802096694
Classification
Generic
Dosage Form
GEL
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
ERYTHROMYCINApproval Type
Generic (ANDA)
FDA Application
ANDA063211FDA Approved
1/29/1993
TE Code
AT
On Market Since
6/12/2008
Pharmacological Classes
Price Statistics
The NADAC for ERYTHROMYCIN 2% GEL has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 14.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6726 per GM |
|---|---|
| All-time high | $3.9949 (Apr 13, 2016) |
| All-time low | $0.4933 (Jul 17, 2024) |
| 52-week high | $0.6864 |
| 52-week low | $0.5978 |
| Median price | $1.3228 |
| Average price | $1.7510 |
| Largest weekly change | +355.9% (Feb 18, 2015) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Padagis Israel Pharmaceuticals Ltd manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Erythromycin market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Macrolide Antimicrobial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ERYTHROMYCIN 2% GEL?
The current National Average Drug Acquisition Cost (NADAC) for ERYTHROMYCIN 2% GEL, manufactured by Padagis Israel Pharmaceuticals Ltd, is $0.6726 per GM (NDC 45802096694), effective Sep 30, 2026.
How has the price of ERYTHROMYCIN 2% GEL changed over time?
Over the history we have for it, the NADAC for ERYTHROMYCIN 2% GEL has declined 14.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ERYTHROMYCIN 2% GEL?
Since Nov 28, 2013, the NADAC for ERYTHROMYCIN 2% GEL has ranged from a low of $0.4933 (Jul 17, 2024) to a high of $3.9949 (Apr 13, 2016), with a median of $1.3228 per GM.
Are there cheaper alternatives to ERYTHROMYCIN 2% GEL?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as ERYTHROMYCIN 2% GEL in a comparable dosage form, but none are currently priced below it.
Who manufactures ERYTHROMYCIN 2% GEL?
ERYTHROMYCIN 2% GEL (NDC 45802096694) is labeled by Padagis Israel Pharmaceuticals Ltd, and CMS classifies it as a generic product.